Drugs / DS-1594b
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04752163 | Mar 2021 → Nov 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1594b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04752163 ↗ |
| Known as | DS-1594a·succinate | “We evaluated the preclinical efficacy of DS-1594a as well as DS-1594a·HCl (the HCl salt of DS-1594a) and DS-1594a·succinate (the succinic acid salt of DS-1594a, DS-1594b) in...” PMID 36841758 ↗ Feb 2023 |
| Route | Oral | “Patients receive DS-1594b orally (PO) twice daily (BID) on days 1-28.” NCT04752163 ↗ |